Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (92)

« Back to Publications

Controlled human malaria infection in adults identify combinations of merozoite antigens associated with clinical immunity.

Ogwang R. et al, (2026), Nat Commun

Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.

Rosenkranz M. et al, (2024), Life Sci Alliance, 7

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.

Nkumama IN. et al, (2024), Immunity, 57, 1215 - 1224.e6

Antibody-Dependent Respiratory Burst against Plasmodium falciparum Merozoites in Individuals Living in an Area with Declining Malaria Transmission.

Mutemi DD. et al, (2024), Vaccines (Basel), 12

Integrating vaccines and monoclonal antibodies into malaria prevention.

Taylor TE. and Osier F., (2024), Nat Med, 30, 37 - 38

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.

Odera DO. et al, (2023), Sci Transl Med, 15

Malaria - Epidemiology, Treatment, and Prevention.

Baden L. et al, (2023), N Engl J Med, 388

Characterization of a novel Plasmodium falciparum merozoite surface antigen and potential vaccine target.

Niaré K. et al, (2023), Front Immunol, 14

Malaria attributable fractions with changing transmission intensity: Bayesian latent class vs logistic models.

Mwai K. et al, (2022), Malar J, 21

Asplenia and spleen hypofunction.

Lenti MV. et al, (2022), Nat Rev Dis Primers, 8

Full-length merozoite surface protein 1 of Plasmodium falciparum is a major target of protective immunity following controlled human malaria infections

Rosenkranz M. et al, (2022)

Breadth of Fc-mediated effector function delineates grades of clinical immunity following human malaria challenge

Nkumama IN. et al, (2022)

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.

Musasia FK. et al, (2022), Nat Commun, 13

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response.

Kapulu MC. et al, (2022), BMC Infect Dis, 22

Distinct kinetics of antibodies to 111 Plasmodium falciparum proteins identifies markers of recent malaria exposure.

Yman V. et al, (2022), Nat Commun, 13

Load More

1
2
3
4
5
6
7